Spero Therapeutics, Inc. (SPRO)
| Market Cap | 362.99M |
| Revenue (ttm) | 17.42M |
| Net Income (ttm) | -79.10M |
| Shares Out | 32.32M |
| EPS (ttm) | -2.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 119,729 |
| Open | 11.36 |
| Previous Close | 11.40 |
| Day's Range | 10.92 - 11.60 |
| 52-Week Range | 10.86 - 22.24 |
| Beta | 1.53 |
| Analysts | Strong Buy |
| Price Target | 41.50 (+269.5%) |
| Earnings Date | n/a |
About SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for SPRO stock is "Strong Buy." The 12-month stock price forecast is 41.50, which is an increase of 269.55% from the latest price.
News
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administer...
New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 million New award option exercised by BARDA brings the total potential funding fr...
FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program
The FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. The SPR720 program was placed on a clinical hold b...
Spero (SPRO) Application for UTI Drug Gets Priority Review
Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 ...
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Tre...
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022 The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022
Spero Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November ...
CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinar...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors
Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero's Board Ms. Tregoning brings more than two decades of experience in biotechnology and public policy t...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners
Spero Therapeutics Inc (NASDAQ: SPRO) has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to $125 million. Spero will use the proceeds to prepare for the ant...
Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® ...
Investment expected to extend Spero Therapeutics' cash runway into 2H 2023 Investment expected to extend Spero Therapeutics' cash runway into 2H 2023
Spero Therapeutics to Present Data at IDWeek 2021
CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializi...
Spero Therapeutics to Present at Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializin...
Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO)
Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 18.18% and 101.88%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Spero Therapeutics Q2 Earnings
Shares of Spero Therapeutics (NASDAQ:SPRO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 25.88% over the past year to ($0.63), whic...
Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update
Tebipenem HBr on track for NDA submission in the fourth quarter of 2021
Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Spero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5,...
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializin...
Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
DuPont De Nemours, Inc Among Today's Trending Stocks
Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified DuPont De Nemours, Inc among others.
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in e...
SHANGHAI, July 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products for patients in Grea...